Combination therapy with remdesivir and immunomodulators improves respiratory status in COVID-19: A retrospective studyArticle Published on 2022-12-012022-11-15 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 치료제, [키워드] 95% confidence interval Analysis Baricitinib baseline benefit body mass index combination therapy Concomitant contributed control group coronavirus disease COVID-19 COVID-19 patient COVID-19 patients Day Diabetes Mellitus examined faster greater hazard ratio immunomodulator immunomodulators IMPROVE in both group independent investigated median outcome Oxygen administration Patient patients Prognostic factors Remdesivir respiratory recovery retrospective Retrospective study severity single-center study standard treatment supplemental oxygen survival synergistic therapy Tocilizumab tocilizumab. treated two group [DOI] 10.1002/jmv.28037 PMC 바로가기
SARS-CoV-2 quasi-species analysis from patients with persistent nasopharyngeal sheddingArticle Published on 2022-11-042022-11-16 Journal: Scientific Reports [Category] SARS, 변종, [키워드] Analysis asked both groups clade Consequences Control COVID 19 deviation Evolution of SARS-CoV-2 genomic greater Human immune system immune evasion increase Infectious virus Interaction intra-individual investigated Mutation N501Y nasopharyngeal no significant difference P681H pandemic Patient patients performed persistence Prevent question RNA virus SARS-CoV-2 Sequencing Standard survival the SARS-CoV-2 therapeutic two group Variability variants viral propagation viral variant [DOI] 10.1038/s41598-022-22060-z PMC 바로가기
Mortality and Deep Vein Thrombosis in the Gamma Variant of Covid 19 and Lung InjuryArticle Published on 2022-11-032022-11-16 Journal: Vascular Health and Risk Management [Category] SARS, 변종, [키워드] affecting Analysis chi-square test clinical suspicion Coagulation complications conducted COVID-19 Critically ill patient deep Deep vein Deep vein thrombosis determine DVT Factor Fisher Gamma greater had more hospital infected individual inhibitor intensive care involved lesion less lung mechanism medical record Mortality occurred Patient patients with SARS-CoV-2 positive Prevalence pulmonary pulmonary injury Pulmonary thrombosis. Retrospective study SARS-CoV-2 disease severe lung injury t -test thrombosis thrombotic event Treatment two group variant Vein Venous thrombosis [DOI] 10.2147/VHRM.S367930 PMC 바로가기
Comparative study of the usefulness of risk score assessment in the early stages of COVID-19 affected pregnancies: Omicron variant versus previous variantsArticle Published on 2022-11-012022-11-16 Journal: The journal of obstetrics and gynaecology research [Category] SARS, 변종, 치료기술, [키워드] affected age Blood C-reactive protein Comparative Course COVID-19 D-dimer level Delta Deterioration disease disease onset early stage Epidemic evaluate examination findings Frequency group groups less no significant difference not significantly different omicron Omicron variant parameter Patient Platelet Pneumonia Pregnancy pregnant Prognosis risk risk scoring significantly lower two group utility variant Variant of concern. variants was increased worsening [DOI] 10.1111/jog.15387 PMC 바로가기
Does timing matter on tocilizumab administration? Clinical, analytical and radiological outcomes in COVID-19Article Published on 2022-11-012022-11-15 Journal: European Journal of Hospital Pharmacy [Category] SARS, 진단, [키워드] 30-Day mortality Administered administration adverse event adverse events analysed Biomarker C-reactive protein clinical Clinical improvement cohorts of patient comparable complementary Complementary therapies coronavirus disease COVID-19 Critical Critical care decrease Efficacy epidemiologically group hospitalised Hypothesis inflammatory parameters knowledge lactate dehydrogenase medication Mortality onset of symptom outcome Patient patients with COVID-19 pharmacological treatment Pneumonia Primary outcome pulmonary medicine Quotient radiological radiological improvement Radiology. randomised controlled trial reductions in SaO_{2} secondary Severe COVID-19 pneumonia statistically significant difference subgroup subgroups the timing therapy Tocilizumab tocilizumab administration two group were recorded while [DOI] 10.1136/ejhpharm-2020-002669 PMC 바로가기
Viral load of SARS-CoV-2 Omicron is not high despite its high infectivityArticle Published on 2022-11-012022-11-16 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, [키워드] acute respiratory syndrome caused cell receptor coronavirus coronavirus disease COVID-19 Delta delta variant examined Factors Genotype genotyping Immune escape median melting curve analysis nasopharyngeal no significant difference omicron Omicron variant Patient PCR performed polymerase chain Quantitative replaced SARS-CoV-2 Sequencing Spread Transmissibility two group variant Viral load Viral load. virus [DOI] 10.1002/jmv.27974 PMC 바로가기
The effect of Nutrition Bio-shield superfood (NBS) on disease severity and laboratory biomarkers in patients with COVID-19: A randomized clinical trialArticle Published on 2022-11-012022-11-15 Journal: Microbial pathogenesis [Category] SARS, 바이오마커, [키워드] ALP assigned baseline body temperature can be used clinical clinical trial Clinical trial study control group COVID-19 COVID-19 disease COVID-19 disease severity CPK CRP determine dimer disease severity Effect effective ELISA kit ESR IL-6 immune system IMPROVE Intervention intervention group Iran laboratory biomarker laboratory biomarkers laboratory parameter LDH lymphocyte Lymphocyte count nutrition Nutrition bio-shield superfood. oxygen saturation Patient patients with COVID-19 performed Placebo Randomized randomized clinical trial receiving Result Serum level serum sample SGOT SGPT significant decrease significant increase single-blind Superfood Tehran tested the mean TNF-α Treatment Trial two group Two-arm variable was performed WBC [DOI] 10.1016/j.micpath.2022.105792 PMC 바로가기
Multi-inflammatory Index as a Novel Mortality Predictor in Critically Ill COVID-19 PatientsArticle Published on 2022-11-012022-11-15 Journal: Journal of Intensive Care Medicine [Category] 바이오마커, [키워드] Analysis analyzed Biomarker C-reactive protein Combination coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patient CRP dead Efficacy group help ICU Ill in-hospital mortality index Inflammation inflammatory parameter inflammatory parameters intensive care intensive care unit investigated lymphocyte median age medical record Mortality multi-inflammatory index. multiple logistic regression NLR Non-survivors novel Pathogenesis patients significantly higher survived survivor systemic systemic inflammation two group [DOI] 10.1177/08850666221100411 PMC 바로가기
Severity predictors of COVID-19 in SARS-CoV-2 variant, delta and omicron period; single center studyArticle Published on 2022-10-252022-11-16 Journal: PLoS ONE [Category] COVID19(2023년), SARS, 변종, [키워드] acute respiratory syndrome Analysis analyzed Appropriate BMI body mass index cause caused changes in Characteristics city Comorbidities coronavirus coronavirus disease COVID-19 COVID-19 severity cut-off value Dyspnea groups Hospitalization laboratory data LDH management moderate Moderate COVID-19 multiple logistic regression Omicron variant outcome Patient predictor progression renal dysfunction SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants sensitivity severe COVID-19 Sex significant difference significantly single center smoking sore throat specificity Symptoms the disease time Treatment treatment regimens two group university vaccination variant Yokohama [DOI] 10.1371/journal.pone.0273134 PMC 바로가기
Six-month humoral immune response to inactivated COVID-19 vaccine among people living with HIVArticle Published on 2022-10-172022-11-15 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 진단, [키워드] 95% CI conducted Control COVID-19 COVID-19 vaccine Day decrease determine dropped Effect ELISA enrolled examined extension FIVE geometric geometric mean concentration GMC GMCs humoral humoral immune response IgG IgG antibody inactivated Inactivated COVID-19 vaccine investigated longitudinal longitudinal humoral response NAb Neutralizing Neutralizing antibodies no significant difference peaked People living with HIV (PLWH) PLWH positive SARS-CoV-2 neutralizing antibody Seroconversion seroconversion rate seroconversion. Seven significantly significantly lower specific IgM two group two groups vaccination with HIV [DOI] 10.3389/fimmu.2022.988304 PMC 바로가기